title: Immunohistochemical expression of IMP3 and p53 in inflammatory lesions and neoplastic lesions of the gastric mucosa.
abstract: OBJECTIVE
  Expression of the oncofetal protein insulin like growth factor II messenger ribonucleic acid binding protein 3 (IMP3) has been shown to differentiate between benign and malignant lesions in several tissues. Our aim was to assess the immunohistochemical expression of IMP3 in inflammatory and neoplastic lesions of the gastric mucosa and to determine whether IMP3, alone or in combination with p53, could be used for identifying neoplasia of the gastric mucosa.
  
  
  METHODS
  IMP3 and p53 immunohistochemistry was performed on 57 cases of gastritis, 28 cases of dysplasia of the gastric mucosa and 63 cases of gastric carcinomas. Focal IMP3 positivity was detected in 86% of non-neoplastic lesions of the gastric mucosa. Using a simple product score (PS), 96% of non-neoplastic lesions of the gastric mucosa were assessed as IMP3(PS) negative. None of the low-grade dysplasia but 83% of high-grade dysplasia were IMP3(PS) positive. Gastric carcinomas showed IMP3(PS) positivity in 65%. Adding p53 to the diagnostic panel increased sensitivity significantly.
  
  
  CONCLUSIONS
  High-grade dysplasia and gastric carcinomas can be distinguished from low-grade dysplasia and inflammatory lesions of the gastric mucosa with a high specificity and good sensitivity using a combination of the immunohistochemical markers IMP3 and p53.
authors: Institute of Pathology, University Hospital Erlangen-Nuremberg 91054 Erlangen, Germany.
authors: Johanna D
authors: JD
authors: Strehl
authors: Institute of Human Genetics, University Hospital Ulm 89081 Ulm, Germany.
authors: Josef
authors: J
authors: Hoegel
authors: Institute of Human Genetics, University Hospital Ulm 89081 Ulm, Germany.
authors: Ines
authors: I
authors: Hornicek
authors: Institute of Pathology, University Hospital Erlangen-Nuremberg 91054 Erlangen, Germany.
authors: Arndt
authors: A
authors: Hartmann
authors: Institute of Pathology, University Hospital Erlangen-Nuremberg 91054 Erlangen, Germany.
authors: Marc-Oliver
authors: MO
authors: Riener
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis*; D001706:Biopsy; D002277:Carcinoma / Q000737:chemistry* / Q000473:pathology; D049109:Cell Proliferation; D003937:Diagnosis, Differential; D005753:Gastric Mucosa / Q000737:chemistry* / Q000473:pathology; D005756:Gastritis / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D060787:Neoplasm Grading; D011237:Predictive Value of Tests; D016601:RNA-Binding Proteins / Q000032:analysis*; D013274:Stomach Neoplasms / Q000737:chemistry* / Q000473:pathology; D016159:Tumor Suppressor Protein p53 / Q000032:analysis*
chemical_list: D014408:Biomarkers, Tumor; C498780:IGF2BP3 protein, human; D016601:RNA-Binding Proteins; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53
keywords: IMP3; gastric mucosa; immunohistochemistry; inflammatory; neoplastic; p53